Systemic AML
In Vivo Screen
Unlock comprehensive insights about your therapeutic in our exclusive cohort of primary patient AML models.
Study Design & Overview
Champions' AML In Vivo Screen includes 30 primary models of Acute Myeloid Leukemia (AML) and is enrolling until April 30, 2024. Each model is representative of complex AML subtypes to successfully recapitulate disease profiles. Champions uses primary patient models that are never passaged and are engrafted systemically to preserve unique patient characteristics.
-
Complete model characterization (clinical data, NGS analysis, proteomics, phospho-proteomics, and kinase activity)
-
Terminal flow cytometry analysis on peripheral blood and bone marrow
-
AML Engraftment Assessement using Champions' Standard systemic AML In Vivo engraftment panel: CD3, CD33, CD34,CD38, mCD45, hCD45, CD117, CD123, Viability Dye
-
Plasma-based Luminex available
Champions' Industry-leading Clinical Annotation & Multi-omic Characterization
AML In Vivo Screen: Terminal Bone Marrow Flow Cytometry Results